Modest financial incentives and gamification encouraged people with cardiovascular risks to meaningfully increase daily step counts over 18 months, in the BE ACTIVE trial.
ApoA1 infusions in acute MI did not significantly reduce the composite endpoint in the AEGIS-II trial. However, an exploratory analysis suggested benefit at higher LDL levels.
ONDA CERO CATALONIA PROGRAM FOR HEALTH, HEALTH EDUCATION AND QUALITY OF LIFEThe entire program is in good hands, with Carles Aguilar. Hospital de Sant Pau
New analysis of the REDUCE-IT trial suggested benefit of icosapent ethyl doesn't vary by Lp(a) level and confirmed risk for Lp(a) with high triglycerides but not cholesterol.
A phase 1 gene editing trial in patients with heterozygous familial hypercholesterolemia and atherosclerotic CVD was paused after abnormal lab results were seen.